Genetic Stock (NASDAQ:GENE)


RevenueOwnershipFinancialsChart

Previous Close

$0.75

52W Range

$0.67 - $3.75

50D Avg

$0.82

200D Avg

$1.80

Market Cap

$6.52M

Avg Vol (3M)

$42.64K

Beta

0.50

Div Yield

-

GENE Company Profile


Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

AU

Employees

55

IPO Date

Sep 06, 2005

Website

GENE Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 22
Asia Pacifics-
Europe MiddleEast and Africa-

Fiscal year ends in Jun 23 | Currency in AUD

GENE Financial Summary


Jun 23Jun 22Jun 21
RevenueAU$8.69MAU$6.79MAU$120.55K
Operating IncomeAU$-9.92MAU$-4.29MAU$-7.06M
Net IncomeAU$-11.75MAU$-7.13MAU$-7.21M
EBITDAAU$-9.24MAU$-3.71MAU$-7.06M
Basic EPS-AU$-0.46AU$-0.51
Diluted EPS-AU$-0.46AU$-0.51

Fiscal year ends in Jun 23 | Currency in AUD

Latest Earnings Call Transcripts


Q4 23Aug 09, 23 | 12:11 AM
Q3 23May 03, 23 | 11:45 PM
Q2 23Feb 27, 23 | 7:56 PM

Peer Comparison


TickerCompany
HTGMHTG Molecular Diagnostics, Inc.
BIOCBiocept, Inc.
AAgilent Technologies, Inc.
SQLSeqLL Inc.
SERASera Prognostics, Inc.
TTOOT2 Biosystems, Inc.
BIAFbioAffinity Technologies, Inc.
INBSIntelligent Bio Solutions Inc.
PRPOPrecipio, Inc.
MDXHMDxHealth SA